European countries can keep using AstraZeneca's coronavirus vaccine during an investigation into cases of blood clots that prompted Denmark, Norway and Iceland to suspend jabs, the EU's drug regulator has said.

There had been 30 cases of 'thromboembolic events' among five million people who've had the jab so far in Europe, the Amsterdam-based European Medicines Agency (EMA) said in a statement, according to AFP.

“The position of EMA's safety committee ... is that the vaccine's benefits continue to outweigh its risks and the vaccine can continue to be administered while investigation of cases of thromboembolic events is ongoing,” the EMA said.

“There is currently no indication that vaccination has caused these conditions, which are not listed as side effects with this vaccine.”